Literature DB >> 28828707

Pathology and diagnosis of renal non-AL amyloidosis.

Sanjeev Sethi1, Jason D Theis2.   

Abstract

Renal amyloidosis is characterized by acellular Congo red positive deposits in the glomeruli, interstitium and/or arteries. Light chain restriction on immunofluorescence studies is present in AL-amyloidosis, the most common type of amyloidosis involving the kidney. The detection of Congo red positive deposits coupled with negative immunofluorescence studies is highly suggestive of non-AL amyloidosis. Some of the non-AL amyloidosis are common while others are relatively rare. The clinical features, laboratory and renal pathology findings are helpful in the diagnosis and typing of non-AL amyloidosis. Thus, ALECT2 amyloidosis is characterized by diffuse cortical interstitial amyloid deposits, AA amyloidosis shows vascular deposits in addition to the glomerular deposits, AFib amyloidosis is characterized by massive amyloid accumulation limited to the glomeruli resulting in the obliteration of glomerular architecture, AApoA1 and AApoAIV are characterized by large amyloid deposits restricted to the medulla, and AGel shows swirling patterns of amyloid fibrils on electron microscopy. While light microscopy is very helpful, accurate typing of non-AL amyloidosis then requires immunohistochemical or laser microdissection/mass spectrometry studies of the Congo red positive deposits. Immunohistochemical studies are available for some of the non-AL amyloidosis. On the other hand, mass spectrometry analysis is a one stop methodology for confirmation and typing of amyloidosis. The diagnosis and typing of amyloidosis by mass spectrometry is based on finding the signature amyloid peptides, apolipoprotein E and serum amyloid-P component, followed by detection of precursor amyloidogenic protein such as LECT2, fibrinogen-α, gelsolin, etc. To, summarize, non-AL amyloidosis is a group of amyloidosis with distinctive clinical, laboratory and renal pathology findings. Typing of the amyloidosis is best performed using mass spectrometry methodology. Accurate typing of non-AL amyloidosis is imperative for correct management, prognosis, and genetic counseling.

Entities:  

Keywords:  ALECT2; Amyloid; Apolipoproteins; Fibrinogen alpha; Gelsolin; Laser-microdissection; Mass spectrometry

Mesh:

Substances:

Year:  2017        PMID: 28828707     DOI: 10.1007/s40620-017-0426-6

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  50 in total

1.  Hereditary renal amyloidosis associated with a novel mutation in the apolipoprotein AII gene.

Authors:  R De Gracia; E J Fernández; C Riñón; R Selgas; J Garcia-Bustos
Journal:  QJM       Date:  2006-02-27

2.  Recurrent AA amyloidosis in a kidney transplant.

Authors:  Sanjeev Sethi; Mireille El Ters; Srividya Vootukuru; Qi Qian
Journal:  Am J Kidney Dis       Date:  2011-04-15       Impact factor: 8.860

3.  Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis; Nelson Leung; Angela Dispenzieri; Samih H Nasr; Mary E Fidler; Lynn D Cornell; Jeffrey D Gamez; Julie A Vrana; Ahmet Dogan
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

4.  Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene.

Authors:  C P Maury; J Kere; R Tolvanen; A de la Chapelle
Journal:  FEBS Lett       Date:  1990-12-10       Impact factor: 4.124

5.  A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene.

Authors:  M D Benson; J J Liepnieks; M Yazaki; T Yamashita; K Hamidi Asl; B Guenther; B Kluve-Beckerman
Journal:  Genomics       Date:  2001-03-15       Impact factor: 5.736

6.  Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome.

Authors:  J Meretoja
Journal:  Ann Clin Res       Date:  1969-12

7.  Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis.

Authors:  Sanjeev Sethi; Surendra Dasari; Md Shahrier Amin; Julie A Vrana; Jason D Theis; Mariam P Alexander; Paul J Kurtin
Journal:  Kidney Int       Date:  2017-01-29       Impact factor: 10.612

8.  Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis.

Authors:  Surendra Dasari; Md Shahrier Amin; Paul J Kurtin; Julie A Vrana; Jason D Theis; Karen L Grogg; Mariam P Alexander; Samih H Nasr; Fernando C Fervenza; Nelson Leung; Sanjeev Sethi
Journal:  Kidney Int       Date:  2016-06-02       Impact factor: 10.612

9.  Hereditary renal amyloidosis with a novel variant fibrinogen.

Authors:  T Uemichi; J J Liepnieks; M D Benson
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis.

Authors:  Sanjeev Sethi; Julie A Vrana; Jason D Theis; Nelson Leung; Anjali Sethi; Samih H Nasr; Fernando C Fervenza; Lynn D Cornell; Mary E Fidler; Ahmet Dogan
Journal:  Kidney Int       Date:  2012-04-11       Impact factor: 10.612

View more
  10 in total

1.  The Changing Spectrum of Heroin-Associated Kidney Disease.

Authors:  Sanjeev Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-15       Impact factor: 8.237

Review 2.  Fibrinogen alpha amyloidosis: insights from proteomics.

Authors:  Jessica Chapman; Ahmet Dogan
Journal:  Expert Rev Proteomics       Date:  2019-08-28       Impact factor: 3.940

Review 3.  Systemic amyloidosis: moving into the spotlight.

Authors:  Oliver C Cohen; Ashutosh D Wechalekar
Journal:  Leukemia       Date:  2020-04-09       Impact factor: 11.528

Review 4.  The tissue proteome in the multi-omic landscape of kidney disease.

Authors:  Markus M Rinschen; Julio Saez-Rodriguez
Journal:  Nat Rev Nephrol       Date:  2020-10-07       Impact factor: 28.314

5.  Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.

Authors:  Pirunthan Perampalam; Haider M Hassan; Grace E Lilly; Daniel T Passos; Joseph Torchia; Patti K Kiser; Andrea Bozovic; Vathany Kulasingam; Frederick A Dick
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

6.  Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.

Authors:  Roberta Fenoglio; Simone Baldovino; Michela Ferro; Savino Sciascia; Gianluca Rabajoli; Giacomo Quattrocchio; Giulietta Beltrame; Carla Naretto; Daniela Rossi; Mirella Alpa; Antonella Barreca; Mario Giulio Papotti; Dario Roccatello
Journal:  J Nephrol       Date:  2020-05-29       Impact factor: 3.902

7.  Apolipoprotein CII Amyloidosis Associated With p.Lys41Thr Mutation.

Authors:  Sanjeev Sethi; Surendra Dasari; Emmanuelle Plaisier; Pierre Ronco; Samih H Nasr; Isabelle Brocheriou; Jason D Theis; Julie A Vrana; Michael T Zimmermann; Patrick S Quint; Ellen D McPhail; Paul J Kurtin
Journal:  Kidney Int Rep       Date:  2018-04-22

8.  Renal Amyloidosis: A Clinicopathological Study From a Tertiary Care Hospital in Pakistan.

Authors:  Safina Ahmed; Humaira Nasir; Ambreen Moatasim; Fareeha Khalil
Journal:  Cureus       Date:  2022-01-11

Review 9.  Renal amyloidosis: a new time for a complete diagnosis.

Authors:  V A Feitosa; P D M M Neves; L B Jorge; I L Noronha; L F Onuchic
Journal:  Braz J Med Biol Res       Date:  2022-10-03       Impact factor: 2.904

Review 10.  New 'Antigens' in Membranous Nephropathy.

Authors:  Sanjeev Sethi
Journal:  J Am Soc Nephrol       Date:  2020-12-30       Impact factor: 10.121

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.